Lintuzumab

Drug Profile

Lintuzumab

Alternative Names: Anti-CD33 MAb; HuM 195; SGN-33

Latest Information Update: 15 Sep 2010

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer Seattle Genetics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD33 antigen inhibitors; Cytokine inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 13 Sep 2010 Discontinued - Phase-I for Myelodysplastic syndromes in USA (IV)
  • 13 Sep 2010 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
  • 09 Jun 2009 Efficacy and safety data from a phase I trial in acute myeloid leukaemia and myeloproliferative diseases presented at the 14th Congress of the European Hematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top